American Renal Associates Holdings Inc (ARA) Expected to Announce Earnings of $0.15 Per Share
Equities analysts forecast that American Renal Associates Holdings Inc (NYSE:ARA) will post $0.15 earnings per share (EPS) for the current fiscal quarter, according to Zacks Investment Research. Two analysts have provided estimates for American Renal Associates’ earnings. The lowest EPS estimate is $0.13 and the highest is $0.18. American Renal Associates reported earnings per share of $0.26 during the same quarter last year, which would indicate a negative year over year growth rate of 42.3%. The company is scheduled to announce its next earnings report on Tuesday, March 6th.
According to Zacks, analysts expect that American Renal Associates will report full-year earnings of $0.56 per share for the current fiscal year, with EPS estimates ranging from $0.54 to $0.59. For the next fiscal year, analysts forecast that the company will post earnings of $0.73 per share, with EPS estimates ranging from $0.69 to $0.79. Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that that provide coverage for American Renal Associates.
Several brokerages recently commented on ARA. SunTrust Banks set a $20.00 price objective on American Renal Associates and gave the stock a “buy” rating in a research note on Thursday, December 21st. Zacks Investment Research downgraded American Renal Associates from a “hold” rating to a “sell” rating in a research note on Tuesday, January 23rd. Finally, Leerink Swann reissued an “outperform” rating and issued a $17.00 price target (down previously from $22.00) on shares of American Renal Associates in a research note on Tuesday, November 21st. One investment analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. American Renal Associates currently has an average rating of “Buy” and a consensus price target of $18.25.
Several institutional investors and hedge funds have recently added to or reduced their stakes in ARA. Schwab Charles Investment Management Inc. raised its stake in shares of American Renal Associates by 0.7% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 39,132 shares of the company’s stock valued at $726,000 after purchasing an additional 285 shares during the period. Bank of New York Mellon Corp raised its stake in shares of American Renal Associates by 13.4% in the 2nd quarter. Bank of New York Mellon Corp now owns 41,288 shares of the company’s stock valued at $766,000 after purchasing an additional 4,874 shares during the period. JPMorgan Chase & Co. raised its stake in shares of American Renal Associates by 2,089.4% in the 2nd quarter. JPMorgan Chase & Co. now owns 72,250 shares of the company’s stock valued at $1,340,000 after purchasing an additional 68,950 shares during the period. Wells Fargo & Company MN raised its stake in shares of American Renal Associates by 21.1% in the 2nd quarter. Wells Fargo & Company MN now owns 14,482 shares of the company’s stock valued at $268,000 after purchasing an additional 2,520 shares during the period. Finally, Alliancebernstein L.P. raised its stake in shares of American Renal Associates by 3.0% in the 2nd quarter. Alliancebernstein L.P. now owns 13,900 shares of the company’s stock valued at $258,000 after purchasing an additional 400 shares during the period. 93.65% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION WARNING: This report was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another domain, it was copied illegally and reposted in violation of international trademark & copyright laws. The correct version of this report can be read at https://www.thecerbatgem.com/2018/02/14/american-renal-associates-holdings-inc-ara-expected-to-announce-earnings-of-0-15-per-share.html.
About American Renal Associates
American Renal Associates Holdings, Inc is a dialysis service provider in the United States focused on joint venture (JV) partnerships with physicians. As of December 31, 2016, the Company owned and operated 214 dialysis clinics in partnership with 379 nephrologist partners treating over 14,000 patients in 25 states and the District of Columbia.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for American Renal Associates Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for American Renal Associates and related companies with MarketBeat.com's FREE daily email newsletter.